Jan Klatt

2.0k total citations · 1 hit paper
43 papers, 1.4k citations indexed

About

Jan Klatt is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Jan Klatt has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Psychiatry and Mental health, 19 papers in Pathology and Forensic Medicine and 9 papers in Physiology. Recurrent topics in Jan Klatt's work include Migraine and Headache Studies (35 papers), Trigeminal Neuralgia and Treatments (18 papers) and Sympathectomy and Hyperhidrosis Treatments (9 papers). Jan Klatt is often cited by papers focused on Migraine and Headache Studies (35 papers), Trigeminal Neuralgia and Treatments (18 papers) and Sympathectomy and Hyperhidrosis Treatments (9 papers). Jan Klatt collaborates with scholars based in United States, Germany and Switzerland. Jan Klatt's co-authors include Uwe Reuter, Peter J. Goadsby, Shihua Wen, Peggy Hours-Zesiger, Daniel D. Mikol, Michel D. Ferrari, Michel Lantéri‐Minet, Hernàn Picard, Messoud Ashina and Sunfa Cheng and has published in prestigious journals such as The Lancet, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Jan Klatt

43 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

2018 332 citations Uwe Reuter, Peter J. Goadsby et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Klatt United States	18	1.3k	926	490	134	120	43	1.4k
Ernesto Aycardi United States	14	1.2k 1.0×	846 0.9×	509 1.0×	108 0.8×	136 1.1×	32	1.4k
Joe Hirman United States	18	1.5k 1.2×	1.1k 1.2×	675 1.4×	131 1.0×	134 1.1×	53	1.8k
Melissa Grozinski‐Wolff United States	5	1.2k 0.9×	808 0.9×	465 0.9×	116 0.9×	123 1.0×	7	1.2k
David Doležil United States	10	914 0.7×	657 0.7×	336 0.7×	103 0.8×	90 0.8×	27	992
Tricia Blankenbiller United States	4	893 0.7×	620 0.7×	367 0.7×	87 0.6×	102 0.8×	8	962
Giorgio Lambru United Kingdom	23	1.3k 1.1×	967 1.0×	511 1.0×	264 2.0×	165 1.4×	80	1.6k
Hille Koppen Netherlands	15	768 0.6×	472 0.5×	237 0.5×	123 0.9×	157 1.3×	40	1.0k
César Ramón Spain	11	768 0.6×	473 0.5×	330 0.7×	226 1.7×	107 0.9×	18	922
Yngve Hallström United States	8	807 0.6×	492 0.5×	265 0.5×	137 1.0×	70 0.6×	11	964
Jo Bonner United States	8	782 0.6×	522 0.6×	297 0.6×	63 0.5×	94 0.8×	11	868

Countries citing papers authored by Jan Klatt

Since Specialization

Citations

This map shows the geographic impact of Jan Klatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Klatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Klatt more than expected).

Fields of papers citing papers by Jan Klatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Klatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Klatt. The network helps show where Jan Klatt may publish in the future.

Co-authorship network of co-authors of Jan Klatt

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Klatt. A scholar is included among the top collaborators of Jan Klatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Klatt. Jan Klatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tepper, Stewart J., Richard B. Lipton, Stephen D. Silberstein, et al.. (2023). Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache The Journal of Head and Face Pain. 63(6). 730–742. 5 indexed citations

Lampl, Christian, et al.. (2022). Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. The Journal of Headache and Pain. 23(1). 104–104. 14 indexed citations

Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2021). Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. The Journal of Headache and Pain. 22(1). 81–81. 11 indexed citations

Lantéri‐Minet, Michel, Peter J. Goadsby, Uwe Reuter, et al.. (2021). Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study. Journal of Neurology Neurosurgery & Psychiatry. 92(5). 466–472. 14 indexed citations

Mikol, Daniel D., et al.. (2020). Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab (1214). Neurology. 94(15_supplement). 1 indexed citations

Goadsby, Peter J., Uwe Reuter, Yngve Hallström, et al.. (2020). One-year sustained efficacy of erenumab in episodic migraine. Neurology. 95(5). e469–e479. 45 indexed citations

Reuter, Uwe, Todd J. Schwedt, David Kudrow, et al.. (2019). Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies. European Journal of Neurology. 26. 637–637. 2 indexed citations

Dodick, David W., Stewart J. Tepper, Hans‐Christoph Diener, et al.. (2019). Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure (S38.002). Neurology. 92(15_supplement). 2 indexed citations

Chou, Denise E., Peter J. Goadsby, Uwe Reuter, et al.. (2019). Sustained Efficacy Over 1 Year of Treatment With Erenumab: Results From the Extension Phase of the STRIVE Study in Episodic Migraine (S38.005). Neurology. 92(15_supplement). 3 indexed citations

10.

Reuter, Uwe, Peter J. Goadsby, Michel Lantéri‐Minet, et al.. (2019). Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study (P1.10-002). Neurology. 92(15_supplement). 3 indexed citations

11.

Reuter, Uwe, Todd J. Schwedt, David Kudrow, et al.. (2019). Long-term Efficacy of Erenumab in Patients With Episodic Migraine Who Have Failed Prior Preventive Migraine Therapies (P1.10-020). Neurology. 92(15_supplement). 3 indexed citations

12.

Schwedt, Todd J., Uwe Reuter, Stewart J. Tepper, et al.. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain. 19(1). 92–92. 72 indexed citations

13.

Reuter, Uwe, Peter J. Goadsby, Michel Lantéri‐Minet, et al.. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet. 392(10161). 2280–2287. 332 indexed citations breakdown →

14.

Goadsby, Peter J., Koen Paemeleire, Gregor Broessner, et al.. (2017). Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s). Ghent University Academic Bibliography (Ghent University). 8 indexed citations

15.

Assaf, Alexandre T., S. Hillerup, J. Rostgaard, et al.. (2015). Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure. International Journal of Oral and Maxillofacial Surgery. 45(2). 245–254. 27 indexed citations

16.

Assaf, Alexandre T., Jan Klatt, Marco Blessmann, et al.. (2015). Value of intra- and post-operative cone beam computed tomography (CBCT) for positioning control of a sphenopalatine ganglion neurostimulator in patients with chronic cluster headache. Journal of Cranio-Maxillofacial Surgery. 43(3). 408–413. 10 indexed citations

17.

Fleischhaker, Christian, Klaus Hennighausen, Philip Heiser, et al.. (2010). A Double-Blind, Randomized, Placebo/Active Controlled Crossover Evaluation of the Efficacy and Safety of Ritalin ^® LA in Children with Attention-Deficit/Hyperactivity Disorder in a Laboratory Classroom Setting. Journal of Child and Adolescent Psychopharmacology. 20(5). 377–385. 20 indexed citations

18.

Schulz, Eberhard, Christian Fleischhaker, Klaus Hennighausen, et al.. (2010). A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks. ADHD Attention Deficit and Hyperactivity Disorders. 2(3). 133–138. 3 indexed citations

19.

Haessler, Frank, Ferenc Tracik, Hartmut Dietrich, Holger Stammer, & Jan Klatt. (2008). A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 46(9). 466–476. 16 indexed citations

20.

Klatt, Jan, et al.. (2001). Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. Journal of Neuroimmunology. 119(1). 137–144. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact